<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347879</url>
  </required_header>
  <id_info>
    <org_study_id>PCTA206/11</org_study_id>
    <nct_id>NCT01347879</nct_id>
  </id_info>
  <brief_title>A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris</brief_title>
  <official_title>PCTA206/11 A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi Center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the efficacy and safety of Visonac Photodynamic Therapy
      (PDT) in patients with severe acne, score 4 on global IGA scale. The null hypothesis is that
      Visonac PDT is equal to vehicle PDT against the alternative hypothesis that Visonac PDT is
      different compared to vehicle PDT at week 12.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules).</measure>
    <time_frame>From baseline to 12 weeks after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</measure>
    <time_frame>From baseline to 12 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Counts.</measure>
    <time_frame>From baseline to 12 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Success According to IGA Scale Based on the Facial Assessment.</measure>
    <time_frame>From baseline to 12 weeks after first treatment</time_frame>
    <description>One Investigator Global Assessment (IGA) scale was used including inflammatory and non-inflammatory lesions. The investigator qualitatively graded the overall acne severity on a scale from 0 to 4, with 4 being the most severe. Success was defined as an improvement of at least 2 grades from the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain During Illumination.</measure>
    <time_frame>Immediately after first treatment</time_frame>
    <description>Pain during illumination was assessed by patient using a Visual Analogue Scale (VAS) from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events.</measure>
    <time_frame>From administration of investigational medicinal product (IMP) until 12 weeks after first IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score of Mild and Moderate</measure>
    <time_frame>Immediately after first treatment</time_frame>
    <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clear and Almost Clear Scarring According to Scarring Score</measure>
    <time_frame>at week 12 after first treatment</time_frame>
    <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</measure>
    <time_frame>From baseline to 12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score of Severe</measure>
    <time_frame>Immediately after first treatment</time_frame>
    <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score of Mild and Moderate</measure>
    <time_frame>2 days after first treatment</time_frame>
    <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Score of Severe</measure>
    <time_frame>2 days after first treatment</time_frame>
    <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mild and Moderate Scarring According to Scarring Score</measure>
    <time_frame>at week 12 after first treatment</time_frame>
    <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe and Very Severe Scarring According to Scarring Score</measure>
    <time_frame>at week 12 after first treatment</time_frame>
    <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Visonac cream with PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with light dose of 37 Joule/cm2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream with PDT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment, Light dose 37 Joule/cm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visonac PDT</intervention_name>
    <description>cream application prior to illumination with red light</description>
    <arm_group_label>Visonac cream with PDT</arm_group_label>
    <other_name>red light</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream with PDT</intervention_name>
    <description>placebo/vehicle cream application prior to illumination with red light</description>
    <arm_group_label>Vehicle cream with PDT</arm_group_label>
    <other_name>red light</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients, from 12-35 years of age with severe facial acne vulgaris
             (IGA score 4 on IGA scale)

          -  Signed and verified informed consent form and photo consent form. For subjects under
             age of 18, an assent form in conjunction with an informed consent form, signed and
             verified by parent/guardian.

          -  Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent,
             or willing to use an adequate means of contraception including birth control pills, or
             barrier methods and spermicide for at least 14 days prior to T1. Patients using birth
             control pills must have used the same product and dose for at least 3 months and must
             agree to stay with the same product and dose for an additional 3 months.

          -  Fitzpatrick skin type I through VI,

          -  Patients with 25 to 75 inflammatory lesions (papules, pustules, and nodules) on the
             face.

          -  Patients with 20 to 100 non-inflammatory lesions (open and closed comedones) on the
             face.

        Exclusion Criteria:

          -  Patients with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced
             acne, etc.)

          -  Patients with more than 3 nodules on the face.

          -  Patient is the investigator or any sub investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the study.

          -  Patients unlikely to comply with the protocol, e.g. mental condition rendering the
             patient unable to understand the nature, scope, and possible consequences of the
             clinical study, uncooperative attitude or unlikelihood of completing the study (e.g.
             drug or alcohol abuse).

          -  Female patients with childbearing potential (i.e. ovulation, pre-menopausal, not
             surgically sterilized) and sexually active, not willing to use a medically accepted
             contraceptive regimen (as described under inclusion criteria) while on treatment.

          -  Pregnancy.

          -  Nursing.

          -  Participation in other clinical studies either currently or within the last 30 days.

          -  Patients with porphyria.

          -  Patients with cutaneous photosensitivity.

          -  Known allergy to MAL, to a similar PDT compound, or to excipients of the cream

          -  Patients using testosterone, any other systemic hormonal treatment or hormonal
             contraceptives solely for control of acne.

          -  Patients who have received topical treatments for their facial acne within the last 14
             days (e.g steroids, retinoids, glycolic acid, benzoyl peroxide, anti inflammatory
             agents, antibiotics). Medicated cleansers may be used during the washout period and
             stopped before the treatment.

          -  Patients who have received oral antibiotics for treatment of their acne within the
             last month.

          -  Patients who have received oral isotretinoin within the last 6 months.

          -  Patient who have received facial procedures like dermabrasion, chemical or laser peels
             within the last 1 month.

          -  Patients using testosterone, any systemic hormonal treatment for other reasons than
             acne treatment and has not been on the same product and dose for at least 3 months

          -  Patients with moderate, severe or very severe facial acne scarring according to
             scarring scale described in section 10.4.3.

          -  Patients with a beard that might interfere with study assessments.

          -  Patients with melanoma or dysplastic nevi in the treatment area.

          -  Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the
             last 30 days

          -  Exposure to PDT within 12 weeks before T1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pariser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Specialists Inc</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Dermatology Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Institute, DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Inc</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research Inc</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>10830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>September 23, 2013</results_first_submitted>
  <results_first_submitted_qc>December 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2014</results_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>PDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dermatology clinics in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
        </group>
        <group group_id="P2">
          <title>Visonac Cream With PDT</title>
          <description>active treatment with light dose of 37 J/cm2
Visonac photodynamic therapy (PDT): cream application prior to illumination with red light</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
        </group>
        <group group_id="B2">
          <title>Visonac Cream With PDT</title>
          <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="5.8"/>
                    <measurement group_id="B2" value="18.6" spread="5.5"/>
                    <measurement group_id="B3" value="18.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin type</title>
          <description>Fitzpatrick skin type. The Fitzpatrick Scale:
Type I (scores 0–7) Light, pale white. Always burns, never tans
Type II (scores 8–16) White; fair. Usually burns, tans with difficulty
Type III (scores 17–24) Medium, white to olive. Sometimes mild burn, gradually tans to olive.
Type IV (scores 25–30) Olive, moderate brown. Rarely burns, tans with ease to a moderate brown.
Type V (scores over 30) Brown, dark brown. Very rarely burns, tans very easily
Type VI Black, very dark brown to black. Never burns, tans very easily, deeply pigmented.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Skin type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules).</title>
        <time_frame>From baseline to 12 weeks after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules).</title>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="21.4"/>
                    <measurement group_id="O2" value="-15.6" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>Lesion count at baseline and center as covariates</method_desc>
            <param_type>Difference in least square means</param_type>
            <param_value>-7.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</title>
        <time_frame>From baseline to 12 weeks after the first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</title>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="22.1"/>
                    <measurement group_id="O2" value="-11.8" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8527</p_value>
            <method>ANCOVA</method>
            <method_desc>Lesion count at baseline and center as covariates</method_desc>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Counts.</title>
        <time_frame>From baseline to 12 weeks after the first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Counts.</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.6" lower_limit="-100" upper_limit="176"/>
                    <measurement group_id="O2" value="-43.8" lower_limit="-100" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>Lesion count at baseline and center as covariates</method_desc>
            <param_type>Difference in least square means</param_type>
            <param_value>-20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.2</ci_lower_limit>
            <ci_upper_limit>-6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Success According to IGA Scale Based on the Facial Assessment.</title>
        <description>One Investigator Global Assessment (IGA) scale was used including inflammatory and non-inflammatory lesions. The investigator qualitatively graded the overall acne severity on a scale from 0 to 4, with 4 being the most severe. Success was defined as an improvement of at least 2 grades from the baseline score.</description>
        <time_frame>From baseline to 12 weeks after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Success According to IGA Scale Based on the Facial Assessment.</title>
          <description>One Investigator Global Assessment (IGA) scale was used including inflammatory and non-inflammatory lesions. The investigator qualitatively graded the overall acne severity on a scale from 0 to 4, with 4 being the most severe. Success was defined as an improvement of at least 2 grades from the baseline score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain During Illumination.</title>
        <description>Pain during illumination was assessed by patient using a Visual Analogue Scale (VAS) from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.</description>
        <time_frame>Immediately after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Pain During Illumination.</title>
          <description>Pain during illumination was assessed by patient using a Visual Analogue Scale (VAS) from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.</description>
          <units>VAS score in cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.0" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.38" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events.</title>
        <time_frame>From administration of investigational medicinal product (IMP) until 12 weeks after first IMP administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score of Mild and Moderate</title>
        <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
        <time_frame>Immediately after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score of Mild and Moderate</title>
          <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clear and Almost Clear Scarring According to Scarring Score</title>
        <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
        <time_frame>at week 12 after first treatment</time_frame>
        <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Clear and Almost Clear Scarring According to Scarring Score</title>
          <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
          <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</title>
        <time_frame>From baseline to 12 weeks after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Non-inflammatory Lesion Count (Open and Closed Comedones)</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" lower_limit="-100" upper_limit="196"/>
                    <measurement group_id="O2" value="-31.0" lower_limit="-100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7161</p_value>
            <method>ANCOVA</method>
            <method_desc>Lesion count at baseline and center as covariate</method_desc>
            <param_type>Difference in least square means</param_type>
            <param_value>-2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>11.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score of Severe</title>
        <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
        <time_frame>Immediately after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score of Severe</title>
          <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score of Mild and Moderate</title>
        <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
        <time_frame>2 days after first treatment</time_frame>
        <population>Of the 100 patients who were included in the Visonac treatment arm, 5 dropped out prior to the day 2 erythema assessment. The number of patients with erythema data at this assessment point is 95.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score of Mild and Moderate</title>
          <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
          <population>Of the 100 patients who were included in the Visonac treatment arm, 5 dropped out prior to the day 2 erythema assessment. The number of patients with erythema data at this assessment point is 95.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Score of Severe</title>
        <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
        <time_frame>2 days after first treatment</time_frame>
        <population>Of the 100 patients who were included in the Visonac treatment arm, 5 dropped out prior to the day 2 erythema assessment. The number of patients with erythema data at this assessment point is 95.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Score of Severe</title>
          <description>Clinical assessment using a 4 point scale; none, mild, moderate, severe</description>
          <population>Of the 100 patients who were included in the Visonac treatment arm, 5 dropped out prior to the day 2 erythema assessment. The number of patients with erythema data at this assessment point is 95.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mild and Moderate Scarring According to Scarring Score</title>
        <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
        <time_frame>at week 12 after first treatment</time_frame>
        <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Mild and Moderate Scarring According to Scarring Score</title>
          <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
          <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe and Very Severe Scarring According to Scarring Score</title>
        <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
        <time_frame>at week 12 after first treatment</time_frame>
        <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
          <group group_id="O2">
            <title>Visonac Cream With PDT</title>
            <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
          </group>
        </group_list>
        <measure>
          <title>Severe and Very Severe Scarring According to Scarring Score</title>
          <description>Clinical assessment using a 6 point scale; Clear, Almost clear, Mild, Moderate, Severe and Very severe</description>
          <population>100 patients were included and 83 patients completed the study in the Visonac treatment arm. However, a few patients came back for the week 12 visit only, and have data for scarring. The total number of patients with scarring data at 12 weeks in this group is 91.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
        </group>
        <group group_id="E2">
          <title>Visonac Cream With PDT</title>
          <description>active treatment with light dose of 37J/cm2
Visonac PDT : cream application prior to illumination with red light</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr David Pariser</name_or_title>
      <organization>Virginia Clinical Research, Inc.</organization>
      <phone>757-625-0151</phone>
      <email>dpariser@pariserderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

